UNSPSC 51321813: Serfibrate

This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 910906N64M. European Medicines Agency schedules Serfibrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10492MIG. Serfibrate generally arises in the molecular formula C16H20CLNO5S.

UNSPSC 51321813 Serfibrate is a Commodity code covering advanced life support and emergency medications supplied to state and local health and public safety agencies. State and local governments procure specific pharmaceutical line items—including vasopressors, antiarrhythmics, and cardiac medications—for use by fire rescue services, health agencies, and multistate cooperative purchasing programs. Issuing bodies include city purchasing departments (Tampa), state health and human services agencies (Texas), and multistate cooperative alliances (Minnesota). Scope varies from small sealed-bid procurements for immediate operational stock to large multistate manufacturer contracts distributing through authorized wholesalers. The code captures both direct municipal purchases of critical-care medications and agency participation in cooperative purchasing vehicles that establish standing supply relationships across multiple jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (370 units of Labetalol, 1,810 units of Epinephrine, 330 units of Adenosine, 1,020 units of Diltiazem) with a response deadline of April 8, 2026 and an estimated contract value of $40,000, with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission released RFI HHS0017013 in April 2026 to assess vendor capacity for a Direct-to-Manufacturer Prescriptions program, soliciting market intelligence on direct contracting capabilities outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026 for generic multi-source pharmaceuticals and OTC products, requiring vendors to maintain relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with contracts effective July 1, 2026. All procurements require FDA compliance, current Good Manufacturing Practices certification, comprehensive insurance (general liability of $5,000,000), and Safety Data Sheets compliant with OSHA standards.